Form 10-Q Editas Medicine, Inc. For: Mar 31
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Wall St set to open lower after AI-led selloff; SpaceX worries hit telecoms
- Meta's capital-raising plans expose a major weakness in the AI boom
- Brent crude hits more than five-month high on Houthi-Saudi attacks, UAE oil spill
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
- AMD shares fall amid AI chip sector selloff
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- JetBlue shares fall amid American results, fuel cost concerns
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Nokia shares fall despite earnings beat on cash flow concerns
Editas Medicine (EDIT) Posts Q1 GAAP Loss of 80c/Share
May 16, 2016 6:29 AM EDTEditas Medicine (NASDAQ: EDIT) reported Q1 EPS of ($0.80), which may not compare with the analyst estimate of ($0.30). Revenue for the quarter came in at $805 thousand versus the consensus estimate of $1.08 million.
For earnings history and earnings-related data on Editas Medicine (EDIT) click here.
... More


